PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.

Clinical trials of CD19-specific chimeric antigen receptor (CAR19) T cells have demonstrated remarkable efficacy against relapsed and refractory B cell malignancies. The piggyBac transposon system offers a less complex and more economical means for generating CAR19 T cells compared to viral vectors. We have previously optimized a protocol for the generation of CAR19 T cells using the piggyBac system， but we found that CAR19 T cells had poor in vivo efficacy and persistence， probably due to deleterious FcγR interactions with the CAR's IgG1 Fc-containing spacer domain. We therefore designed three CD19-specifc CARs that lacked the IgG1 Fc region， and we incorporated combinations of CD28 or 4-1BB transmembrane and co-stimulatory domains. PiggyBac-generated CAR19 T cells expressing these re-designed constructs all demonstrated reactivity in vitro specifically against CD19 cell lines. However， those combining CD28 transmembrane and co-stimulatory domains showed CD4 predominance and inferior cytotoxicity. At high doses， CAR19 T cells were effective against B-ALL in a xenograft mouse model， regardless of co-stimulatory domain. At diminishing doses， 4-1BB co-stimulation led to greater potency and persistence of CAR19 T cells， and it provided protection against B-ALL re-challenge. Production of potent CAR T cells using piggyBac is simple and cost-effective， and it may enable wider access to CAR T cell therapy.